Related Experiment Video

Updated: Jun 15, 2025

Osteoclast Derivation from Mouse Bone Marrow
06:17

Osteoclast Derivation from Mouse Bone Marrow

Published on: November 6, 2014

24.1K

Role of osteoclast inhibitors in prostate cancer bone metastasis; a narrative review

Shariq Ahmad Wani1, Salma Qudrat2, Hina Zubair3

  • 1Department of Internal Medicine, Government medical college, Srinagar, India.

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|August 22, 2024
PubMed
Abstract

Insights

Osteoclast inhibitors, such as bisphosphonates and denosumab, effectively reduce skeletal events in advanced prostate cancer bone metastasis. These treatments improve patient quality of life by managing pain and preventing fractures.

Area of Science:

  • Oncology
  • Pharmacology
  • Bone Metastasis Research

Background:

  • Prostate cancer frequently metastasizes to the skeleton, causing significant morbidity including pain, fractures, and spinal cord compression.
  • Skeletal-related events (SREs) substantially reduce quality of life and increase disability in patients with advanced prostate cancer.
  • Historically, radiation and radiopharmaceuticals were primary treatments for bone metastases.

Purpose of the Study:

  • To evaluate the role of osteoclast inhibitors in treating advanced prostate cancer metastasis.
  • To assess the efficacy of osteoclast inhibitors in reducing skeletal-related events (SREs).

Main Methods:

  • A comprehensive literature search was conducted on PubMed and Google Scholar.
  • Keywords included "osteoclast inhibitors," "Bisphosphonates," "Zoledronic acid," "pamidronate," "Alendronate," "Denosumab," and "Prostate cancer metastasis."
  • Relevant articles were screened, collected, and synthesized to review the use of osteoclast inhibitors in prostate cancer bone metastasis.

Main Results:

  • Osteoclast inhibitors, including bisphosphonates and denosumab, are now integral to managing metastatic prostate cancer.
  • These agents significantly decrease the incidence of SREs.
  • Emerging therapies like Radium-223 show promise in reducing SREs and improving survival.
  • Other treatments like chemotherapy (Docetaxel, cabazitaxel), hormonal therapies (abiraterone, enzalutamide), and immunotherapy (sipuleucel-T) are also utilized.

Conclusions:

  • Osteoclast inhibitors are effective in mitigating SREs in advanced prostate cancer with bone metastasis.
  • These therapies demonstrably improve the quality of life for affected patients.
Keywords:
Bonebisphosphonatesmetastasisosteoclast inhibitorsprostate cancer

More Related Videos

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

4.6K
Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

16.3K

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.9K
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Role of Vitamins in Maintaining Bone Health01:25

Role of Vitamins in Maintaining Bone Health

The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
3.2K